Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 15/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5334220 | 0.89 | AURKA (0.46) | AURKAKDRNR1H2SRD5A2GHSR | |
| SCHEMBL5328430 | 0.86 | AURKA (0.55) | AURKAKDRNR1H2SRD5A2GHSR | |
| SCHEMBL5327142 | 0.79 | NR1H2 (0.51) | AURKAKDRNR1H2ATRATRIP | |
| SCHEMBL5463892 | 0.78 | AURKA (0.51) | AURKAKDRSRD5A2 | |
| SCHEMBL5332483 | 0.77 | NR1H2 (0.38) | AURKAKDRNR1H2SRD5A2ATR | |
| SCHEMBL3037160 | 0.77 | ATR (0.40) | NR1H2ATRATRIPBRD4CREBBP | |
| SCHEMBL3920246 | 0.76 | NR1H2 (0.41) | NR1H2SRD5A2NR1H3 | |
| SCHEMBL3840220 | 0.75 | ATR (0.35) | AURKAKDRNR1H2ATRATRIP | |
| SCHEMBL3858581 | 0.75 | NR1H2 (0.40) | AURKAKDRNR1H2ATRATRIP | |
| SCHEMBL3834957 | 0.74 | ATR (0.38) | NR1H2ATRATRIPNR1H3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-12 | — | — | US | disclosed |
| WO-2007047646-A2 | SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161648-A1 | Substituted dihydro-isoindolones useful in treating kinase disorders | MAP3K20, MAP3K3, MAP3K19 | AURKA 669/4885KDR 1627/4885NR1H2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.